within Pharmacolibrary.Drugs.ATC.C;

model C03DA05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.43,
    Cl             = 0.00042833333333333335,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0526,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0012833333333333334,
    Tlag           = 19.8,            
    Vdp             = 0.119,
    k12             = 69.8,
    k21             = 69.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C03DA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist used in the treatment of chronic kidney disease (CKD) associated with type 2 diabetes. It is approved for reducing the risk of kidney function decline, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in this patient group.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration of finerenone.</p><h4>References</h4><ol><li><p>Heinig, R, et al., &amp; Halabi, A (2019). Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment. <i>European journal of drug metabolism and pharmacokinetics</i> 44(5) 619–628. DOI:<a href=&quot;https://doi.org/10.1007/s13318-019-00547-x&quot;>10.1007/s13318-019-00547-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30825073/&quot;>https://pubmed.ncbi.nlm.nih.gov/30825073</a></p></li><li><p>Lentini, S, et al., &amp; Wensing, G (2016). Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies. <i>Fundamental &amp; clinical pharmacology</i> 30(2) 172–184. DOI:<a href=&quot;https://doi.org/10.1111/fcp.12170&quot;>10.1111/fcp.12170</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26604072/&quot;>https://pubmed.ncbi.nlm.nih.gov/26604072</a></p></li><li><p>Heinig, R, et al., &amp; Loewen, S (2022). Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers. <i>European journal of drug metabolism and pharmacokinetics</i> 47(4) 549–559. DOI:<a href=&quot;https://doi.org/10.1007/s13318-022-00770-z&quot;>10.1007/s13318-022-00770-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35612708/&quot;>https://pubmed.ncbi.nlm.nih.gov/35612708</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C03DA05;
